Expanding Orthopedics Inc. has Obtained CE Mark for its Unique FLXfit?, 3D Expandable Interbody Cage - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Expanding Orthopedics Inc. has Obtained CE Mark for its Unique FLXfit?, 3D Expandable Interbody Cage Expanding Orthopedics Inc., announced today that the FLXfit", its novel expandable and articulated TLIF cage with lordotic correction, has received CE Mark.


Expanding Orthopedics Inc. has Obtained CE Mark for its Unique FLXfit™, 3D Expandable Interbody Cage

Expanding Orthopedics Inc., announced today that the FLXfit™, its novel expandable and articulated TLIF cage with lordotic correction, has received CE Mark.

PR Newswire

OR AKIVA, Israel, July 1, 2014 /PRNewswire/ --

Expanding Orthopedics Inc. (EOI), a privately held medical device company focused on developing and commercializing innovative expandable devices for spine surgeryis proud to announce that its novel FLXfit™, 3D expandable interbody cage has received the CE Mark and is now cleared for commercialization in Europe.

Ofer Bokobza, CEO of Expanding Orthopedics, said that "We are very excited with this significant milestone as the FLXfit™ will be the first TLIF cage available worldwide with the 3D expanding capability". He explained that "FLXfit's innovative design is based on EOI's expanding devices' IP portfolio enabling an 'all-in-one' solution for interbody fusion. The FLXfit[ TM ] combines minimal invasive access, maximum footprint support, large bone graft chamber with unique lordotic expansion for optimal anatomical fit".

Mike Sherman of MB Venture Partners, long time spine industry veteran,  investor and director at EOI stated "the $2B market for interbody fusion devices has experienced very limited innovation over the last few decades, considering cages only as spacers or bone graft chambers. New technologies that enable in-situ expansion are now driving  amazing  growth in  this market segment, leading to active and aggressive M&A activity in the last 18 months". Mike added that "My past involvement in the  development of minimally invasive spinal implants has confirmed to me that surgeons are looking for solutions that enable them to restore the anatomical balance in the lumbar spine instead of only stabilizing it. I'm very excited about EOI's FLXfit™, as it will enable surgeons to provide gentle correctionwith an intra-operative expanding device , while restoring the patient's anatomy with  FLXfit's unique lordotic expansion".  

Mr. Ofer Bokobza, stated that "the FLXfit™ represents a game-changer for minimally invasive treatment for lumbar degenerative disc disease while restoring sagittal balance. The articulated self-guidance feature enables easy and optimal access while providing large footprint coupled with controlled expansion for lordotic correction. He further explained that "we plan to initiate surgeries in Europe in the coming weeks with pre-defined centers followed by full release in selected territories. We feel a lot excitement from the medical community and distributors and believe that the FLXfit™ will provide a revenue boost in combination with our unique XPED™ Expandable Pedicle Screw System."

About Expanding Orthopedics Inc. 

Expanding Orthopedics Inc. is a venture backed, medical device company developing and marketing innovative products designed to address unmet clinical needs for spine care and improve long-term patients' outcome. The Company is spearheaded by seasoned management team with proven industry experience, and is backed by prominent spine surgeons. EOI owns a broad patent portfolio around anatomically fit, expandable devices for enhanced stability and fixation through a minimally invasive approach.

Contact info:
David Elkaim
VP Marketing and Sales
E-mail: david@xortho.com

SOURCE Expanding Orthopedics Inc.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here